Antibiotics Used for Urinary Tract Infections in Pregnancy

Antibiotics Used for Urinary Tract Infections in Pregnancy: Comparison

Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Mariela Corrales.

Urinary tract infection (UTI) is considered to be a major problem in pregnant women. It is also one of the most prevalent infections during pregnancy, being diagnosed in as many as 50–60% of all gestations. Therefore, UTI treatment during pregnancy is extremely important and management guidelines have been published worldwide to assist physicians in selecting the right antibiotic for each patient, taking into account the maternal and fetal safety profile.

urinary tract infection
UTI
pregnancy
woman
guideline

1. Introduction

Urinary tract infection (UTI) is considered to be a major problem in pregnant women [1,2,3]^[1][2][3]. It is also one of the most prevalent infections during pregnancy, being diagnosed in as many as 50–60% of all gestations ^[4].

UTIs can be classified as lower urinary tract infections, including both asymptomatic bacteriuria (ASB) or acute cystitis (AC), and upper urinary tract infections or acute pyelonephritis (APN) ^[5]. Most infections are caused by Enterobacteriaceae, commonly found in the gastrointestinal tract, with Escherichia coli (E. coli) being responsible for 80–90% of cases. However, weit can fibe found other bacteria such as Group-B Streptococcus saprophyticus (GBSS), Klebsiella pneumoniae, coagulase-negative Staphylococcus, Staphylococcus aureus and Proteus mirabilis in a lower percentage [2,6]^[2][6].

In pregnant women, ASB occurs in an estimated 2–10% ^[7], and if left untreated, it can turn into symptomatic AC in 30% of patients and may progress to APN in up to 50% of those patients ^[6], which have been associated with several complications for both the mother and the unborn child [2,8]^[2][8].

Therefore, UTI treatment during pregnancy is extremely important and management guidelines have been published worldwide to assist physicians in selecting the right antibiotic for each patient, taking into account the maternal and fetal safety profile [5,6,9]^[5][6][9].

2. Antibiotics in ABU

Without specifying the hierarchy of preference, the recommended antibiotics were: nitrofurantoin [11,15,18^{[10][11][12][13][14]},19,20], trimethoprim/sulfamethoxazole (TMP/SMX) [20]^[14], fosfomycin [11^{[10][11][13][15][16]},12,13,15,19], multiple penicillins such as amoxicillin [15,19^[11][13][14],20], ampicillin [18]^[12], pivmecillinam [11]^[10], ampicillin/sulbactam [21]^[17], amoxicillin/clavulanate [15^[11][14][17],20,21], first-generation cephalosporine (1stGC) such as cephalexin [15,18,19,20,21]^{[11][12][13][14][17]} and second-generation cephalosporine (2ndGC) such as cefuroxime [15,19]^[11][13]. When referring to lines of treatment, as first line, nitrofurantoin [16^[17][18],21], fosfomycin [21]^[17] and amoxicillin [14]^[19] were proposed. Second-line treatments were pivmecillinam [14]^[19], cephalexin [16]^[18] and amoxicillin (if sensible) [16]^[18]. France was the only country that gives up to five-line treatments [14]^[19], with fosfomycin being the third-line treatment; trimethoprim, the fourth-line one; and nitrofurantoin, amoxicillin/clavulanate, cefixime and TMP/SMX, the fifth-line treatment. TMP/SMX was also suggested as the last antibiotic choice in Germany [11]^[10]. Results are summarized in Table 31, including the dosage recommended by each guideline.

Table 31.

Antibiotic treatment for asymptomatic bacteriuria and cystitis during pregnancy.

	Asymptomatic Bacteriuria			Cystitis
Antibiotic (Oral)	Treatment Line: Country/Region	Dosage (Guideline Reference)	Duration (Days)	Treatment Line: Country/Region	Dosage (Guideline Reference)	Duration (Days)
Nitrofurantoin	1st Line:	UK, CO	5th Line:	FR	NS:	DE, IE, USA, AR, BR	100 mg/6–8 [19,20,21] 100 mg/12 h * [11,15,16,21] or 50 mg/6 h [11,16]	100 mg/6–8 ^[13][14]^[17] 100 mg/12 h * ^[10][11]^[17]^[18] or 50 mg/6 h ^[10][18]	5–7 5–7 7	1st Line:	UK, DE, CO	3rd Line:	FR	NS:	DE, IE, AR, BR	100 mg/6–8 [19,20,21] or 100 mg/12 h * [11,15,16] or 50 mg/6 h [11,16]	100 mg/6–8 ^[13][14]^[17] or 100 mg/12 h * ^[10][11]^[18] or 50 mg/6 h ^[10][18]	5–7 5–7 7
Amoxicillin	1st Line:	FR	2nd Line:	UK	NS:	IE, AR, BR	500 mg/8 h [15,16,19] or 875 mg/12 h [19]	500 mg/8 h ^[11][13]^[18] or 875 mg/12 h ^[13]

^[20], cephalexin [22]^[20], amoxicillin [16]^[18] and amoxicillin/clavulanate [12]^[15] were proposed. For second-line treatment the chosen antibiotics were pivmecillinam [14]^[19], cephalexin [16]^[18], penicillins such as amoxicillin [22]^[20] and amoxicillin/clavulanate [22]^[20] and 2ndGC (cefuroxime) [12]^[15]. For third-line treatment, options were nitrofurantoin [14]^[19], ciprofloxacin [14]^[19], TMP/SMX [12]^[15] and third-generation cephalosporine (3rdGC) such as cefixime [14]^[19]. TMP/SMX was also suggested as the last antibiotic choice in Germany [11]^[10]. Results are summarized in Table 31, including the dosage recommended by each guideline.

4. Antibiotics in APN

For APN treatment, most guidelines recommended as a first-line treatment a monotherapy with 3rdGC [13,14,15,20]^{[11][14][16][19]} such as ceftriaxone [15,20]^[11][14] or 2ndGC [7,13]^[7][16] such as cefuroxime [13,17]^[16][21] and, if patient unstable or septic, adding an aminoside such as gentamicin [7,13,15]^[7][11][16] was recommended. Double parental therapy with amoxicillin/gentamicin [7,22]^[7][20] or ampicillin/gentamicin [22]^[20] was also proposed. Second-line treatment included cefuroxime [12]^[15], gentamicin [20]^[14], aztreonam [7^[7][14],20], 2ndGC such as cefuroxime [12]^[15] and 3rdGC (ceftriaxone or cefotaxime) [22]^[20]. Ireland proposed a dual parenteral therapy with clindamycin or vancomycin (based on the susceptibly results) and gentamicin. As a third-line option, France proposed ciprofloxacin in case of beta-lactamase allergy [14]^[19]. The AFU also specified a 10 day-treatment for UTI caused by extended-spectrum beta-lactamase producing E. coli (ESBLE). Ciprofloxacin, levofloxacin or TMP-SMX was the first-line choice, amoxicillin–clavulanate was the second-line choice and cefoxitin, piperacillin–tazobactam or temocillin was the third-line choice. Recommendations for oral therapy switch were: amoxicillin [14^[19][20],22], amoxicillin/clavulanate [14^[19][20],22], cephalexin [22]^[20], trimethoprim [22]^[20], cefixime [14]^[19] or ciprofloxacin [14]^[19]. A couple of European guidelines proposed oral antibiotics for uncomplicated AP: cephalexin (1stGC) [17]^[21] or amoxicillin/clavulanate [12]^[15] as a first-line treatment and TMP/SMX [12]^[15] as third-line treatment. Results are summarized in Table 42, including the dosage recommended by each guideline.

Table 42.

Antibiotic acute pyelonephritis during pregnancy.

Antibiotic	Treatment Line: Country/Region	Dosage (Guideline Reference)	Duration (Days) *	Remarks (Guideline Reference)
Ceftriaxone IV	1st Line:	IE, FR, AR, ES	2nd Line:	AU	1–2 g/24 h [14,,20]	1–2 g/24 h ^[11]	15,22] 1–2 g/24 h [	^[^19]^[20]	13	1–2 g/24 h ^[¹⁴^]^[16]	10–14 or 7–10	If patient unstable: add G (i.e., es) [13,15] If contraindication for G [22] Consider 2 g dose in 2nd/3rd T of pregnancy [15]	If patient unstable: add G (i.e., es) ^[11][16] If contraindication for G ^[20] Consider 2 g dose in 2nd/3rd T of pregnancy ^[11]
Amoxicillin + Gentamicin IV	1st Line:	AU, EU	Ax: 2 g/6 h [7,22] G: 5 mg/kg/24 h [7,22]	Ax: 2 g/6 h ^[7][20] G: 5 mg/kg/24 h ^[7][5 or 7 7	1st Line:	UK	2nd Line:	AU	NS:	IE	²⁰^]	500 mg/8 h [15,16,22]	500 mg/8 h ^[11][	7–14^18]^[20]	5 or 7
Cephalexin (1stGC)	2nd Line:	UK	NS:	IE, USA, AR, CO, BR	500 mg/6–8 h [19,
Ampicillin + Gentamicin IV	1st Line:	AU	20,21] or 500 mg/8–12 [15,16]	500 mg/6–8 h ^[13][14]^[17] or 500 mg/8–12 ^[11][18]	5–7	1st Line:	Ap: 2 g/6 h [22] G: 5 mg/kg/24 h [22]	Ap: 2 g/6 h ^[20] G: 5 mg/kg/24 h ^[20] AU	2nd Line:	UK	10–14	NS:	IE, AR, CO	500 mg/6–8 h [20,		21] or 500 mg/8–12 h [15,16,22]	500 mg/6–8 h ^[14][17] or 500 mg/8–12 h ^[11][18]^[20]	5–7
Pivmecillinam	2nd Line:	FR	N.S:	DE	400 mg/8–12 h [11]	400 mg/8–12 h ^[10]	3 or 7	2nd Line:	FR	NS:
2ndGC ± Aminoside IV	1st Line:	EU	N.A	DE	400 mg/8–12 h [11]	400 mg/8–12 h	7–14^[10]	3 or 7
If sepsis: add aminoside	^[	⁷	^]	Fosfomycin	1st Line:
Cephalexin (1stGC) PO	CO	1st Line:3rd Line	: FR	NS:	IE, DE, EU, CH, ES, BR	UK	3 g [7,	⁷	11,	^]	12,13,	^[^10]^[11]^[13	14,15,19,21]	3 g ^[^]^[^15]^[16]^[	500 mg/8–12 h [17	¹⁷^]^[¹⁹^]	Single dose	]	500 mg/8–12 h	1st Line:	FR, CO	NS:	IE, DE, EU, UK, ES, AR, BR	^[21]	3 g [7,11,13,14,15,16,21]	3 g ^[7]	7–10^[10]^[11]	^[¹⁶^]^[17]^[18]^[19]	Single dose
Trimethoprim	4th Line:	FR	N.A	7	1st Line:	AU	300 mg/24 h [22]
Amoxicillin/Clavulanate PO	1st Line:	CH	300 mg/24 h	1 g/12 h or 625 mg/8 h [12]	1 g/12 h or 625 mg/8 h ^[15][20]	3
5–7		Amoxicillin/ clavulanate	5th Line:	FR	NS:
Cefuroxime (2ndGC)	IE, AR, CO	1st Line:	UK, ES	2nd Line:	CH	875 mg/12 h [20] or 500 mg/8 h [21] or 625 mg/8 h [15]	875 mg/12 h ^[14] or 500 mg/8 h ^[17] or 625 mg/8 h ^[11]	750 mg–1.5 g/6–8 h [	5–7	17] or 500 mg/12 h [12]	750 mg–1.5 g/6–8 h ^[21] or 500 mg/12 h ^[15]	1st Line:	CH	2nd Line:	AU	NS:	IE, CO, BR	7–10 3–5	If PO is not suitable [17] If sepsis: add aminoside [13]	If PO is not suitable ^[21] If sepsis: add aminoside ^[16]	500/125 mg/12 h [19,22] or 875/125 mg/12 h [19] or 500 mg/8 h [21] or 625 mg/8 h [12,15]	500/125 mg/12 h ^[13][20] or 875/125 mg/12 h ^[13] or 500 mg/8 h ^[17] or 625 mg/8 h ^[11][15]	5–7
Cefixime (3rdGC)	5th Line:	FR	N.A	7	3rd Line:	FR	N.A	7
Ciprofloxacin	2nd Line:	FR	NA	7–14		TMP/SMX	5th Line:
Clindamycin + Gentamicin IV	FR	Last line:	DE	2nd Line:NS:	AR	IE	800/160 mg/12 h [11,20]	800/160 mg/12 h ^[10][14]	4–7	3rd Line:	C: 900 mg/8 h G: 1.5 mg/kg/8 h or 5 mg/kg/24 h [15]	C: 900 mg/8 h G: 1.5 mg/kg/8 h or 5 mg/kg/24 h ^[11] CH	Last line:	DE	800/160 mg/12 h [	10	If GBSS: choose vancomycin (1 g/12 h) or clindamycin based on the susceptible results [15]	If GBSS: choose vancomycin (1 g/12 h) or clindamycin based on the susceptible results ^[11]	11,12]	800/160 mg/12 h ^[10][15]	4–7
Cefuroxime (2ndGC)	NS:	IE, BR	250–500 mg/12 h [19]
Cefotaxime IV	2nd Line:	AU	500 mg/12 h [12]	250–500 mg/12 h ^[13] 500 mg/12 h	1 g/8 h [22]	1 g/8 h ^[20^[15]	5–7	^]	2nd Line:	CH	NS:	IE, BR	250 mg/12 h [	10–14	If contraindication for G [22]	If contraindication for G ^[20]	19] 500 mg/12 h [12,	250 mg/12 h ^[	15]	^13] 500 mg/12 h ^[11][15]	5–7
Ampicillin/ sulbactam	NS:	CO
Gentamicin IV/IM	2nd Line:	AR	1.5 g/12 h [21]	1.5 g/12 h ^[17]	5–7
240 mg/24 h [	20	]	240 mg/24 h ^[14]	10	If allergy to beta-lactams [20]	If allergy to beta-lactams ^[	Ampicillin	NS:	USA	N.A	4–7
Ciprofloxacin	-	-	-	3rd Line:	FR	N.A	5–7

NS: Not specified; *: Macrocrystals/Prolonged release; 2ndGC: Second-generation cephalosporin; TMP/SMX: Trimethoprim/Sulfamethoxazole; EU: Europe; CO: Colombia; FR: France; UK: United Kingdom; DE: Germany; IE: Ireland; USA: United States of America; AR: Argentina; BR: Brazil; CH: Switzerland; ES: Spain; AU: Australia.

3. Antibiotics in Cystitis

Without specifying the hierarchy of preference, the recommended antibiotics were: nitrofurantoin [11^{[10][11][13][14]},15,19,20], fosfomycin [7^{[7][10][11][13][14][16][18]},11,13,15,16,19,20], multiple penicillins such as amoxicillin [15]^[11], pivmecillinam [11]^[10], amoxicillin/clavulanate [15^[11][13][17],19,21], 1stGC (cephalexin) [15,20,21]^[11][14][17] and 2ndGC (cefuroxime) [15,19]^[11][13]. When referring to lines of treatment, as first line, nitrofurantoin [11^[10][17][18],16,21], fosfomycin [14^[17][19],21], trimethoprim [22]

¹⁴
^]
Aztreonam IV
2nd Line:
AR, EU
1–2 g/8–12 h [
20
]
1–2 g/8–12 h	^[	^14]	10	If allergy to beta-lactams [20]	If allergy to beta-lactams ^[14]
TMP/SMX	3rd Line: CH	800/160 mg/12 h [12]	800/160 mg/12 h ^[15]	3–5

EU: Europe; FR: France; UK: United Kingdom; DE: Germany; IE: Ireland; AR: Argentina; CH: Switzerland; ES: Spain; AU: Australia; G: Gentamicin; 2nd/3rd T: Second/Third trimester; *: days of parenteral + oral treatment.

References

Waltzer, W.C. The Urinary Tract in Pregnancy. J. Urol. 1981, 125, 271–276.
Matuszkiewicz-Rowińska, J.; Małyszko, J.; Wieliczko, M. Urinary tract infections in pregnancy: Old and new unresolved diagnostic and therapeutic problems. Arch. Med. Sci. 2015, 11, 67–77.
Czajkowski, K.; Broś-Konopielko, M.; Teliga-Czajkowska, J. Urinary tract infection in women. Prz. Menopauzalny Menopause Rev. 2021, 20, 40–47.
Baraka, M.A.; AlLehaibi, L.H.; AlSuwaidan, H.N.; Alsulaiman, D.; Islam, A.; Alotaibi, B.S.; Alboghdadly, A.; Homoud, A.H.; Al-Ghamdi, F.H.; Al Ghamdi, M.S.; et al. Patterns of infections and antimicrobial drugs’ prescribing among pregnant women in Saudi Arabia: A cross sectional study. J. Pharm. Policy Pract. 2021, 14, 9.
Glaser, A.P.; Schaeffer, A.J. Urinary Tract Infection and Bacteriuria in Pregnancy. Urol. Clin. N. Am. 2015, 42, 547–560.
Krischak, M.K.; Rosett, H.A.; Sachdeva, S.; Weaver, K.E.; Heine, R.P.; Denoble, A.E.; Dotters-Katz, S.K. Beyond Expert Opinion: A Comparison of Antibiotic Regimens for Infectious Urinary Tract Pathology in Pregnancy. AJP Rep. 2020, 10, e352–e356.
Bonkat, G.; Pickard, R.; Bartoletti, R.; Cai, T.; Bruyère, F.; Geerlings, S.E.; Köves, B.; Wagenlehner, F. EAU Guidelines on Urological Infections 2018. In European Association of Urology Guidelines; European Association of Urology Guidelines Office: Arnhem, The Netherlands, 2018.
Wing, D.A.; Fassett, M.J.; Getahun, D. Acute pyelonephritis in pregnancy: An 18-year retrospective analysis. Am. J. Obstet. Gynecol. 2014, 210, 219.e1–219.e6.
Ghouri, F.; Hollywood, A. Antibiotic Prescribing in Primary Care for Urinary Tract Infections (UTIs) in Pregnancy: An Audit Study. Med. Sci. 2020, 8, 40.
Kranz, J.; Schmidt, S.; Lebert, C.; Fünfstück, R.; Helbig, S.; Hofmann, W.; Hummers, E.; Kunze, M.; Kniehl, E.; Naber, K.; et al. Interdisziplinäre AWMF S3-Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Nieren-Und Hochdruckkrankheiten 2017, 46, 334–385.
Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive. Clinical Practice Guideline Management of Urinary Tract Infections in Pregnancy. 2018. Available online: https://rcpi-live-cdn.s3.amazonaws.com/wp-content/uploads/2016/05/32.-Management-of-Urinary-Tract-Infections-in-Pregnancy.pdf (accessed on 6 October 2022).
Nicolle, L.E.; Gupta, K.; Bradley, S.F.; Colgan, R.; DeMuri, G.P.; Drekonja, D.; Eckert, L.O.; Geerlings, S.E.; Köves, B.; Hooton, T.M.; et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2019, 68, 1611–1615.
de Rossi, P.; Cimerman, S.; Truzzi, J.C.; da Cunha, C.A.; Mattar, R.; Martino, M.D.V.; Hachul, M.; Andriolo, A.; Neto, J.A.V.; Pereira-Correia, J.A.; et al. Joint report of SBI (Brazilian Society of Infectious Diseases), FEBRASGO (Brazilian Federation of Gynecology and Obstetrics Associations), SBU (Brazilian Society of Urology) and SBPC/ML (Brazilian Society of Clinical Pathology/Laboratory Medicine): Recommendations for the clinical management of lower urinary tract infections in pregnant and non-pregnant women. Braz. J. Infect. Dis. 2020, 24, 110–119.
Nemirovsky, C.; Furst, M.J.L.; Pryluka, D.; De Vedia, L.; Scapellato, P.; Colque, A.; Barcelona, L.; Desse, J.; Caradonti, M.; Varcasia, D.; et al. Consenso Argentino Intersociedades de Infección Urinaria 2018-2019-Parte I. Medicina 2020, 80, 229–240.
Betschart, C.; Albrich, W.C.; Brandner, S.; Faltin, D.; Kuhn, A.; Surbek, D.; Geissbuehler, V. Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy. Swiss Med. Wkly. 2020, 150, w20236.
de Cueto, M.; Aliaga, L.; Alós, J.-I.; Canut, A.; Los-Arcos, I.; Martínez, J.A.; Mensa, J.; Pintado, V.; Rodriguez-Pardo, D.; Yuste, J.R.; et al. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm. Infecc. Microbiol. Clin. 2017, 35, 314–320.
Martinez, E.; Osorio, J.; Delgado, J.; Esparza, G.; Motoa, G.; Blanco, V.; Hernández, C.; Agudelo, A.; Aluma, L.; Betancurt, C.; et al. Infecciones del tracto urinario bajo en adultos y embarazadas: Consenso para el manejo empírico. Infectio 2014, 17, 122–135.
NICE NG109. Urinary Tract Infection (Lower): Antimicrobial Prescribing (October 2018). Available online: https://www.nice.org.uk/guidance/ng113 (accessed on 6 October 2022).
Caron, F.; Galperine, T.; Flateau, C.; Azria, R.; Bonacorsi, S.; Bruyère, F.; Cariou, G.; Clouqueur, E.; Cohen, R.; Doco-Lecompte, T.; et al. Practice guidelines for the management of adult community-acquired urinary tract infections. Méd. Mal. Infect. 2018, 48, 327–358.
Department for Health and Wellbeing G of SA. Urinary Tract Infection in Pregnancy. South Australian Perinatal Practice Guideline 2021. Available online: https://www.sahealth.sa.gov.au (accessed on 6 October 2022).
NICE NG111. Pyelonephritis (Acute): Antimicrobial Prescribing (October 2018). Available online: https://www.nice.org.uk/guidance/ng111 (accessed on 6 October 2022).